25 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
15
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Astex Therapeutics
29
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Astex Therapeutics
92
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
Theravance Respiratory
220
Sulfoximine substituted quinazolines for pharmaceutical compositions
Evotec Internatonal
85
Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
Heptares Therapeutics
20
Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase
Amicus Therapeutics
4
In vitro effects of some anabolic compounds on erythrocyte carbonic anhydrase I and II.
Balikesir University
6
Amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome
Universite De Strasbourg
17
Mild and efficient synthesis of new tetraketones as lipoxygenase inhibitors and antioxidants.
Pharmaceutical Research Centre
1
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
Aventis Pharma
2
Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.
Vrije Universiteit
23
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
U. 109
9
Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.
University of Bologna
15
Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors.
Ohio State University
12
Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
Bristol Myers Squibb